论文部分内容阅读
目的:研究超大剂量顺铂治疗晚期卵巢癌的临床疗效和可行性。方法:对23例FIGO期别≥c的晚期卵巢癌施行超大剂量顺铂(120～150mg/m2)化疗,采用David法计算顺铂的剂量强度、UICC和WHO标准评定临床疗效和毒副反应。结果:共进行100疗程化疗,顺铂剂量强度(DI)3.08±0.92,总剂量强度(TDI)12.08±3.92,临床完全反应率60.86%,有效率65.22%,顺铂DI、TDI和近期疗效无关(P>0.05)。23例中无一例因化疗毒副反应死亡,但出现剂量限制毒性21疗程。初治病例中位生存14个月,无瘤中位生存13个月。结论:超大剂量顺铂治疗晚期卵巢癌难以达到计划顺铂剂量强度,在人体内提高顺铂剂量并不一定改善化疗疗效
Objective: To study the clinical efficacy and feasibility of super large dose of cisplatin in the treatment of advanced ovarian cancer. Methods: Twenty-three patients with advanced ovarian cancer with FIGO stage ≥c were treated with super-high-dose cisplatin (120-150 mg / m2) chemotherapy. The dose intensity of cisplatin was calculated by the method of David. The clinical efficacy and adverse reactions were evaluated by UICC and WHO criteria. Results: A total of 100 courses of chemotherapy were conducted. The dose of cisplatin (DI) 3.08 ± 0.92, total dose intensity (TDI) 12.08 ± 3.92, clinical complete response rate 60.86%, effective rate 65.22%, cisplatin DI, TDI and recent efficacy (P> 0.05). None of 23 patients died of chemotherapy-induced side effects, but dose-limiting toxicities occurred for 21 courses. The median survival of newly diagnosed cases was 14 months, and the median survival time was 13 months. CONCLUSIONS: It is difficult to achieve the planned dose of cisplatin in super-high-dose cisplatin for advanced ovarian cancer. Increasing the dose of cisplatin in human does not necessarily improve the efficacy of chemotherapy